VVP
COGT icon

Venture Visionary Partners’s Cogent Biosciences COGT Stock Holding History

Venture Visionary Partners’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,000
Closed -$18K – 680
2022
Q2 		$18K Buy
+2,000
New +$13.7K ﹤0.01% 1052

Other funds holding COGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Venture Visionary Partners's COGT Position: Q3 2022 in Review

Venture Visionary Partners sold out of Cogent Biosciences (COGT) in Q3 2022, closing a stake of 2,000 shares — an estimated $18K sold.

Venture Visionary Partners first reported a position in COGT in Q2 2022 and held it in 1 quarter. The position peaked at $18K in Q2 2022. 134 funds tracked by Wall St. Rank hold COGT as of Q3 2022.

  • Venture Visionary Partners reported no remaining Cogent Biosciences position as of Q3 2022 after selling out during the quarter.
  • Venture Visionary Partners sold 2,000 Cogent Biosciences shares in Q3 2022, an estimated $18K.
  • Venture Visionary Partners first reported a position in Cogent Biosciences in Q2 2022 and held it in 1 quarter.
  • Venture Visionary Partners's Cogent Biosciences position peaked at $18K in Q2 2022.
  • 134 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.